Indication
Obesity
The Obesity pipeline: 120 tracked drugs, 8 approved for this indication.
8 approved / phase 437 Phase 31 Phase 2/340 Phase 28 Phase 1/224 Phase 12 preclinical / unstaged
Compare the share prices of listed companies in Obesity →
Total attributable cost
$199.1B
$1,861/patient
Drug spend
$10.6B
$99/patient
5% of total cost is drugs
BMI >=30 (or >=27 with a weight-related comorbidity) · US